Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 1091-1102

  Visani, G ^a   Olivieri, A ^b   Malagola, M ^c   Brunori, M ^d   Piccaluga, P P ^e   Capelli, D ^b   Pomponio, G ^b   Martinelli, G ^e   Isidori, A ^a   Sparaventi, G ^a   Leoni, P ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute myeloid leukemia; Chemotherapy; Evidence based medicine; Stem cell transplantation

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; TIOGUANINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DONOR; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; LEUKEMIA REMISSION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RANDOMIZATION; SYSTEMATIC REVIEW;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; REMISSION INDUCTION; RESEARCH DESIGN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33746302522     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500513595     Document Type: Article

References (50)

1. Sackett, D and Rennie, D. (1992) The science of the art of the clinical examination J Am Med Assoc, 267, pp. 2650-2652.
2. Sackett, D. (1997) Evidence-based medicine and treatment choices Lancet, 349, pp. 570.
3. Sackett, D. (1997) Evidence-based medicine Sem Perinathol, 21, pp. 3-5.
4. Sackett, D and Straus, S. (1998) Finding and applying evidence during clinical rounds: The "evidence cart" J Am Med Assoc, 280, pp. 1336-1338.
5. White, K. (1968) Organization and delivery of personal health services. Public policy issues Milbank Mem Fund Quarterly, 46, pp. 225-258.
6. Dubinsky, M and Ferguson, J. (1990) Analysis of the National Institutes of Health Medicare coverage assessment Int J Technol Assess Health Care, 6, pp. 480-488.
7. Hamer, A. (1997) Evidence based practice Physiother Res Int, 2, pp. 59.
8. Mandelli, F and Petti, M and Lo Coco, F. (1998) Therapy of acute myeloid leukemia: Towards a patient-oriented, risk adapted approach Haematologica, 1983, pp. 1015-1023.
9. Estey, E and Thall, P and Beran, M and Katarjian, H and Pierce, S and Keating, M. (1997) Effect of diagnosis (refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation or acute myeloid leukemia) on outcome of AML-type chemotherapy Blood, 90, pp. 2969-2977.
10. Bloomfield, C and Herzig, G and Peterson, B and Wolff, S. (1997) Long term survival of patients with acute myeloid leukemia: A third follow up of the fourth International Workshop on Chromosomes in leukemia Cancer, 80, pp. 2191-2198.
11. Hann, I and Stevens, R and Goldstone, A and Rees, J and Wheatley, K and Gray, R and et al. (1997) Randomized comparison of DAT vs ADE as induction chemotherapy in children and young adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trials (AML MRC 10) Blood, 89, pp. 2311-2318.
12. Rees, J and Gray, G and Wheatley, K. (1996) Dose intensification in acute myeloid leukemia: Great effectiveness at lower costs. Principal report of MRC AML 9 study Br J Haematol, 94, pp. 89-94.
13. Yates, J and Glidewell, O and Wiernik, P and Cooper, M and Steinberg, D and Dosik, H and et al. (1982) Cytosine arabinoside with daunorubicin or adriamycin therapy in AML: A CALGB study Blood, 60, pp. 454-463.
14. Arlin, Z and Case, D and Moore, J and Wuernik, P and Feldman, E and Saletan, S and et al. (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non limphocytic leukemia Leukemia, 4, pp. 177-183.
15. Vogler, W and Velez-Garcia, E and Weiner, R and Flaum, M and Bartolucci, A and Omura, G and et al. (1992) A phase III trial comparing idarubicine and daunorubicin in combination with cytarabine in AML: A Southeastern Cancer Study Group J Clin Oncol, 16, pp. 1103-1111.
16. Lowenberg, B and Sucio, S and Archimbaud, E and Haak, H and Stryckmans, P and de Cataldo, R and et al. (1998) Mitoxantrone vs Daunorubicin in induction-consolidation chemotherapy, the value of low dose cytarabine for maintenance of remission as well as in assessment of prognostic factors in AML in the elderly: The final report of the EORTC LCG-HOVON randomized phase III study AML-19 J Clin Oncol, 16, pp. 1-11.
17. Visani, G and Bernasconi, P and Boni, M and Castoldi, G and Ciolli, S and Clavio, M and et al. (2001) The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia. Analysis of 848 patients Leukemia, 15, pp. 903-909.
18. Suciu, S and Mandelli, F and de Witte, T and Zittoun, R and Gallo, E and Labar, B and et al. (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia in first complete remission: An intent to treat analysis of the EORTC/GIMEMA AML-10 trial Blood, 102, pp. 1232-1240.
19. Dillman, R and Davis, R and Green, M and Weiss, R and Gottlieb, A and Caplan, S and et al. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B Blood, 78, pp. 2520-2526.
20. Bishop, J and Matthews, J and Young, G and Szer, J and Gillett, A and Joshua, D et al. (1996) A randomized trial of high dose cytarabine in induction in acute myeloid leukemia Blood, 87, pp. 1710-1717.
21. Buchner, T and Hiddemann, W and Wormann, B and Loffler, H and Gassmann, W and Haferlach, T and et al. (1999) Double induction strategy for acute myeloid leukemia: The effect of high dose cytarabine with mitoxantrone instead of standard dose cytarabine with daunorubicin and 6-thioguanin: a randomized trial by the German AML Cooperative Group Blood, 93, pp. 4116-4124.
22. Cahn, J and Labopin, M and Sierra, J and Blaise, D and Reiffers, J and Ferrant, A and et al. (2000) No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukemia in first remission Br J Haematol, 110, pp. 308-314.
23. Bradstock, K and Matthews, J and Lowenthal, R and Baxter, H and Catalano, J and Gill, D and et al. (2005) A randomized trial of high versus conventional dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine Blood, 105, pp. 481-488.
24. Bishop, J and Lowenthal, R and Joshua, D and Matthews, J and Todd, D and Cobcroft, R and et al. (1990) Etoposide in acute non lymphocytic leukemia Blood, 75, pp. 27-32.
25. Berman, E and Arlin, Z and Gaynor, J and Miller, W and Gee, T and Kempin, S and et al. (1989) Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non lymphocytitc leukemia: Results of the L-16M protocol Leukemia, 3, pp. 115-121.
26. Rowe, J and Tallmann, M. (1997) Intensifying induction therapy in acute myeloid leukemia: Has a new standard of care emerged? Blood, 90, pp. 2121-2126.
27. Russo, D and Pericolo, G and Michieli, M and Michelutti, A and Raspadori, D and Bertone, D and et al. (2001) Fludarabine, arabinosyl cytosine and idarubicine (FLAI) for remission induction in poor risk AML Leuk Lymphoma, 40, pp. 335-343.
28. Robak, T. (2003) Purine nucleoside analogues in the treatment of myeloid leukemias Leuk Lymphoma, 44, pp. 391-409.
29. Holowiecki, J and Grosicki, S and Robak, T and Kyrcz-Krzemien, S and Giebel, S and Hellmann, A and et al. (2004) Addition of cladribine to daunorubicine and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. A multicenter Phase III study Leukemia, 2, pp. 1-9.
30. Estey, E and Thall, P and Cortes, J and Giles, F and O'Brien, S and Pierce, S and et al. (2001) Comparison of idarubicin + AraC, fludarabine + AraC, topotecan + AraC based regimens in tratment of newly diagnosed acute myeloid leukemia, refractory anemia with excess of blasts Blood, 98, pp. 3575.
31. Tsimberidou, A and Stavroyianni, N and Viniou, N and Papaioannou, M and Tiniakou, M and Marinakis, T and et al. (2003) Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia Cancer, 97, pp. 1721-1731.
32. Piccaluga, P and Martinelli, G and Rondoni, M and Malagola, M and Gaitani, S and Isidori, A and et al. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas Leuk Lymphoma, 45, pp. 1791-1795.
33. Zittoun, R and Mandelli, F and Willemze, R and de Witte, T and Labar, B and Resegotti, L and et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive consolidation chemotherapy in acute myeloid leukemia N Eng J Med, 332, pp. 217-227.
34. Cassileth, P and Harrington, D and Appelbaum, F and Lazarus, H and Rowe, J and Paietta, E and et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Eng J Med, 339, pp. 1649-1656.
35. Gale, R and Buchner, T and Zang, M and Heinecke, A and Champlin, R and Dicke, K and et al. (1996) HLA identical sibling bone marrow transplant vs chemotherapy for acute myeloid leukemia in first remission Leukemia, 10, pp. 1687-1689.
36. Isidori, A and Bonifazi, F and Visani, G and Gherlinzoni, F and Baccarani, M and Lemoli, R. (2005) Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: A 10-year follow-up study of 118 patients Haematologica, 90, pp. 139-141.
37. Harousseau, J and Cahn, J and Pignon, B and Witz, F and Milpied, N and Delain, M and et al. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia Blood, 8, pp. 2978-2986.
38. Burnett, A and Goldstone, A and Stevens, R and Hann, I and Rees, J and Gray, R and et al (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial Lancet, 7, pp. 700-708.
39. Breems, D and Boogaerts, M and Dekker, A and Van Putten, W and Sonneveld, P and Huijgens, P and et al. (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial Br J Haematol, 128, pp. 59-65.
40. Reiffers, J and Gaspard, M and Maraninchi, D and Michallet, M and Marit, G and Stoppa, A and et al. (1989) Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: A prospective controlled trial Br J Haematol, 72, pp. 57-63.
41. Ferrant, A and Doyen, C and Delannoy, A and Cornu, G and Martiat, P and Latinne, D and et al. (1991) Allogeneic or autologous bone marrow transplantation for acute non-lymphocyttic leukemia in first remission Bone Marrow Transplant, 7, pp. 303-309.
42. Burnett, A and Wheatley, K and Goldstone, A and Stevens, R and Hann, I and Rees, J and et al. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: Results of the UK MRC AML 10 trial Br J Haematol, 118, pp. 385-400.
43. Gratwohl, A and Baldomero, H and Passweg, J and Frassoni, F and Niederwieser, D and Schmitz, N, and et al. (2003) Hematopoietic stem cell transplantation for hematological malignancies in Europe Leukemia, 17, pp. 941-959.
44. Reiffers, J and Stoppa, A and Attal, M and Michallet, M and Marit, G and Blaise, D and et al (1996) Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study Leukemia, 10, pp. 1874-1882.
45. Nathan, P and Sung, L and Crump, M and Beyene, J. (2004) Consolidation therapy with autologous bone marrow transplantation in adults with acute myloid leukemia: A meta-analysis J Nat Cancer Instit, 96, pp. 38-45.
46. Bellido, M and Tobias, A and Burnet, S and Sierra, J. (2005) Bone marrow and peripheral blood stem cell transplantation in adult patients in first remission (protocol) The Cochrane Library, 2, pp. 1-11.
47. Guyatt, G and Sackett, D and Cook, D. (1993) Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group J Am Med Assoc, 270, pp. 2598-2601.
48. Guyatt, G and Sackett, D and Cook, D. (1994) Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group J Am Med Assoc, 271, pp. 59-63.
49. Jadad, A and Rennie, D. (1998) The randomized controlled trial gets a middle-aged checkup J Am Med Assoc, 279, pp. 319-320.
50. Levi, I and Grotto, I and Yerushalmi, R and Ben-Bassat, I and Shpilberg, O. (2004) Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission Leuk Res, 28, pp. 605-612.